CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
Habitrol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02265874
NCT02265874Phase 2Completed
CompareCT.gov

Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study

Ohio State University·interventional·Posted Oct 16, 2014·Updated Apr 24, 2025

In Brief

A Phase 2 clinical trial evaluating Habitrol and Placebo to Habitrol for Sarcoidosis. Completed, enrolled 50 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if nicotine treatment is beneficial for the treatment of sarcoidosis. Sarcoidosis is a disease of unknown cause that leads to inflammation. This disease affects your body's organs.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcoidosis
CountriesUnited States
CollaboratorsThe Cleveland Clinic

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 16, 2014
Enrollment StartOct 21, 2015
Primary CompletionNov 1, 2021
TodayJul 2, 2026
Enrollment to primary: 6.0 yearsPosted 11.7 years ago

Interventions

Habitroldrug

Patch used daily for 28 weeks

Placebo to Habitroldrug